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Abstract
AIM: To analyze the change of dimethylarginine 
plasma levels in cirrhotic patients receiving transjugular 
intrahepatic portosystemic shunt (TIPS).
METHODS: To determine arginine, asymmetric 
dimethylarginine (ADMA), symmetric dimethylarginine 
(SDMA), and nitric oxide (NO) plasma levels, blood 
samples were collected from the superior cava, 
hepatic, and portal vein just before, directly after, and 
3 mo after TIPS-placement.
RESULTS: A significant increase in the arginine/ADMA 
ratio after TIPS placement was shown. Moreover, 
TIPS placement enhanced renal function and thereby 
decreased systemic SDMA levels. In patients with renal 
dysfunction before TIPS placement, both the arginine/
ADMA ratio and creatinine clearance rate increased 
significantly, while this was not the case in patients 
with normal renal function before TIPS placement. 
Hepatic function did not change significantly after TIPS 
placement and no significant decline in ADMA plasma 
levels was measured.
CONCLUSION: The increase of the arginine/ADMA 
ratio after TIPS placement suggests an increase 
in intracellular NO bioavailability. In addition, this 
study suggests that TIPS placement does not alter 
dimethylarginine dimethylaminohydrolase (DDAH) 
activity and confirms the major role of the liver as an 
ADMA clearing organ.
© 2008 The WJG Press. All rights reserved.
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INTRODUCTION
In 1977, Carnegie and co-workers[1] pointed out 
the potential role of  the liver in the metabolism of  
asymmetric dimethylarginine (ADMA) by reporting an 
increased urinary excretion of  ADMA in patients with 
liver disease. Later, it was shown in an organ balance 
study in rats that the liver takes up substantial amounts 
of  ADMA, thereby suggesting a crucial role for the liver 
in regulating systemic ADMA concentrations[2]. These 
results were confirmed in patients undergoing hepatic 
surgery in whom it was also shown that the clearing 
of  symmetric dimethylarginine (SDMA) was not only 
confined to the kidney, but the human liver also took 
up small amounts of  SDMA from the portosystemic 
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circulat ion[3]. Elevated ADMA levels have been 
reported in patients eligible for liver transplantation[4,5], 
in postoperative patients undergoing major liver 
resection[6], in patients suffering from decompensated 
alcoholic cirrhosis[7], and in critically ill patients with 
hepatic dysfunction[8]. ADMA plays a regulatory role in 
the arginine-nitric oxide (NO) pathway by inhibiting the 
enzyme NO synthase[9] and by competing with arginine 
and SDMA for cellular transport across cationic amino 
acid transporters (CAT) of  system y+[10]. Both ADMA 
and SDMA are removed from the body by urinary 
excretion. However, the main eliminatory route for 
ADMA is degradation by the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH) which is highly 
expressed in the liver, but is also present in the kidney, 
and in endothelial cells[11,12].
D ime thy l a r g in ine s may p l ay an impor t an t 
pathophysiological role in liver cirrhosis because this 
disease is characterised by endothelial dysfunction and 
NO deficiency in the intrahepatic circulation (review 
article[13]). In fact, increased intrahepatic vascular 
resistance in cirrhosis is not only due to structural 
changes, but also due to a dynamic component. The 
latter has largely been attributed to a reduced intrahepatic 
endothelial NO-synthase activity in liver cirrhosis[14]. 
Indeed, it has been suggested that an alteration in 
hepatic DDAH expression and/or activity in liver 
disease leads to high intrahepatic ADMA levels along 
with resultant endothelial dysfunction and increased 
intrahepatic resistance[15]. In cirrhotic patients, elevated 
peripheral ADMA and NO levels have been reported[7,16] 
and it has been suggested that ADMA might oppose the 
peripheral vasodilation caused by excessive systemic NO 
production during liver cirrhosis[7]. In order to analyze 
the change of  dimethylarginine plasma levels in cirrhotic 
humans, we studied patients receiving transjugular 
intrahepatic portosystemic shunt (TIPS).
MATERIALS AND METHODS
The study was approved by the institutional review board 
and medical ethical review committee of  the University 
Hospital Regensburg in Germany. Before study entry, 
patients were informed on the purpose of  the study and 
informed consent was obtained from all patients.
Patients
The study population consisted of  25 patients suffering 
from liver cirrhosis and undergoing TIPS-placement 
mainly because of  refractory ascites or recurrent 
esophageal variceal bleeding. The etiology of  liver 
cirrhosis was: alcoholic hepatitis (20), viral hepatitis (2), 
cryptogenic hepatitis (2), and myeloproliferative disease 
(1). All patients had severe portal hypertension (portal 
pressure > 12 mmHg) which was determined during 
TIPS-placement. The diagnosis of  liver cirrhosis was 
based on clinical, biochemical, and ultrasonographic 
data. Severity of  hepatic failure was scored according to 
the Child-Pugh Classification[17].
Blood sampling and analysis
Blood samples were collected just before TIPS-
placement from the superior caval vein, hepatic vein, 
and portal vein. Directly after TIPS-implantation and 
-dilation to its final lumen (before ending the procedure 
and dismissing the patient to the ward), and 3 mo after 
placement of  the stent (to investigate patency of  the 
shunt), blood was drawn again from the superior caval 
vein, portal vein and from another hepatic vein to 
prevent sampling from the extended portal venous tract.
ADMA, SDMA, and arginine plasma concentrations 
were measured by high-performance liquid chrom-
atography with fluorescence detection using monomethy-
larginine as internal standard, as previously described[18]. 
After sample cleanup by solid-phase extraction, the 
analytes were derivatized with ortho-phthaldialdehyde 
reagent conta in ing 3-mercaptopropionic ac id . 
Chromatographic separation of  the fluorescent derivatives 
was performed on a monolithic column as recently 
described[19]. Intra-assay coefficients of  variation (CVs) 
were < 1.2% for all analytes. Inter-assay CVs were < 3.0% 
for ADMA and arginine and < 4% for SDMA. Reference 
values for ADMA have been obtained from plasma of  
healthy laboratory personnel and medical students[18]. The 
concentration of  ADMA in these individuals is normally 
distributed. These patients did not have liver or kidney 
diseases and had no diseases that influence ADMA levels.
NOx concentrations were measured using the Nitric 
Oxide Analyzer from Sievers Instruments (Boulder, 
Colorado, USA), as described previously[20,21]. Briefly, 
this assay is based upon spectrophotometric analysis 
after chemiluminescent reaction between NO and ozone 
(detection limit < 1 µmol/L). Creatinine clearance rate 
was calculated from plasma and urinary concentrations 
in 24 h collected urine. Other biochemical parameters 
were determined by standard laboratory methods.
Statistical analysis
Differences between timepoints were tested with 
Wilcoxon signed ranks test. For each comparison, 
the overall α-level was set at 0.05. Relations between 
variables were investigated by Spearman’s rho. Data are 
presented as medians and interquartile ranges (IQR). 
Statistical analyses were performed using SPSS (SPSS 
11.0 for Windows).
RESULTS
Patients
Patient characteristics are presented in Table 1. Hepatic 
synthetic and clearing functions were slightly impaired 
as reflected by decreased factor Ⅴ, antithrombin Ⅲ, 
albumin, and cholinesterase concentrations and slightly 
increased bilirubin levels. Three months after TIPS-
placement, no significant improvement was seen in 
either laboratory parameters of  hepatic function, hepatic 
enzyme concentrations, or Child-Pugh score (data not 
shown).
Although creatinine and urea levels were within the 
normal range, creatinine clearance rate was decreased at 
baseline. Placement of  TIPS enhanced renal function as 
illustrated in Table 2.
Portal and systemic pressures
Portal hypertension was present in all patients. TIPS-
placement caused an immediate decrease in both portal 
pressure and in portosystemic pressure gradient (Table 3). 
After 3 mo, these pressures were still decreased in 
comparison to baseline values.
Concentrations of ADMA, SDMA, and arginine
T he chang es in ADMA, SDMA, and a rg in ine 
concentrations in the systemic, portal, and hepatic vein 
are shown in Table 4. At all 3 three timepoints, median 
systemic ADMA and SDMA plasma levels were higher 
in cirrhotic patients compared to healthy volunteers[18] 
(ADMA: 0.42 µmol/L (0.37-0.47); P < 0.05, SDMA: 
0.46 µmol/L (0.42-0.52); P < 0.05, respectively). In 
contrast, arginine concentrations were lower at baseline 
compared to healthy individuals (arginine: 88 µmol/L 
(76-113); P < 0.05), but did not differ anymore after 
TIPS-placement.
Although ADMA levels did not show a significant 
change due to TIPS-placement, SDMA concentrations 
were significantly lower 3 mo after TIPS-placement 
in comparison to baseline values. Placement of  TIPS 
caused a significant increment of  both arginine levels 
and arginine/ADMA ratios.
When an additional analysis was performed between 
patients with (creatinine clearance rate < 97 mL/min) 
and patients without (creatinine clearance rate > 
97 mL/min) additional renal dysfunction before TIPS 
placement, arginine/ADMA ratio increased significantly 
(P = 0.021) in patients with renal dysfunction; before 
TIPS placement: 94 (81-135) and 3 mo after TIPS 
placement: 124 (99-174). This was also the case for 
creatinine clearance rate which improved significantly 
(P = 0.036) from 44 mL/min (27-70) before TIPS 
placement to 105 mL/min (73-146) 3 mo after TIPS 
placement. In patients with normal renal function, no 
significant changes in either creatinine clearance rate or 
arginine/ADMA ratio was seen.
NOx plasma concentrations
Although NOx plasma levels showed a decreasing 
                                              Demographic data
Number of patients   25
Gender: Male/Female 18/7
Age: Median (range)   55 (40-81)
TIPS indication
   Ascites   20
   Esophageal varices     2
   Others     3
Child-Pugh classification
   A     5
   B   14
   C     6
Biochemical markers of hepatic
function
Median IQR Reference
range
   Bilirubin (mmol/L)   20 13-35 < 17
   Aspartate aminotransferase (U/L)   19 13-34 < 50
   Alanine aminotransferase (U/L)   15 7-27 < 50
   Alkaline phosphatase (U/L) 135 99-185 < 124
   Prothrombin time (%)   72 59-81 > 70
   Factor V (%)   52 40-80 > 75
   Antithrombin (%)   67 48-79 > 75
   Fibrinogen (mg/dL) 299 232-408 180-350
   Albumin (g/L)   35 31-41 37-53
   Cholinesterase (U/L) 2049 1461-2800 5320-12 920
   Alpha-fetoprotein (ng/mL)     3.1 2.5-4.0 < 8.1
Biochemical markers of renal
function
   Urea (mmol/L)   13 8-18 4-18
   Creatinine (µmol/L)   77 59-113 < 97
   Creatinine clearance (mL/min)   80 38-115 97-160
Table 1  Demographic data and parameters of hepatic and
renal function
Table 2  Biochemical markers of renal function
Just before TIPS Directly after TIPS 3 mo after TIPS
Median IQR Median IQR Median IQR
Urea (mmol/L) 13 8-18 12 5-33 11a 5-16
Creatinine 
(µmol/L)
77 59-113 63 54-107 70a 57-89
Creatinine
clearance (mL/min)
80 38-115 110 75-138 128a 97-161
aP < 0.05 vs just before TIPS-placement.
Table 3  Pressure (mmHg) in portal vein and right atrium
Just before TIPS Directly after TIPS 3 mo after TIPS
Median IQR Median IQR Median IQR
Portal vein 30 20-35 23a 16-27 17a 10-23
Right atrium   9   1-12 13a   5-17  6a   2-15
Gradient (pv-ra) 21 19-24 10a   9-11 11a   7-15
Pv: Portal vein; ra: Right atrium. aP < 0.05 vs just before TIPS-placement.
Just before TIPS Directly after TIPS 3 mo after TIPS
Median IQR Median IQR Median IQR
ADMA
   Caval vein 0.64 0.58-0.72 0.69 0.61-0.78 0.59 0.53-0.74
   Portal vein 0.67 0.60-0.79    0.7 0.62-0.80 0.58 0.52-0.77
   Hepatic vein 0.62 0.59-0.71 0.66 0.57-0.84 0.57 0.52-0.74
SDMA
   Caval vein 0.74 0.60-1.16 0.81 0.64-1.11  0.61a 0.46-0.86
   Portal vein 0.79 0.62-1.13 0.72 0.64-1.06  0.62a 0.46-0.89
   Hepatic vein 0.79 0.61-1.09 0.77 0.64-1.09  0.60a 0.44-0.89
Arginine
   Caval vein   64 56-85   76   68-102   77a   65-104
   Portal vein   69 62-93   79   64-102   90a   70-106
   Hepatic vein   54 46-75   67 59-88   72a   57-101
Arginine/ADMA
   Caval vein   95   83-132 117   89-141 128a  110-175
   Portal vein   83   68-123   98   80-130 123a   92-152
   Hepatic vein 108   88-138 114   88-137 141a  112-185
Table 4  Plasma concentrations (µmol/L) of ADMA, SDMA,
and arginine
aP < 0.05 vs just before TIPS-placement.
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tendency after TIPS placement, changes did not reach 
statistical significance (Table 5). 
SDMA concentrations were positively related to 
NOx before and 3 mo after TIPS placement (r = 0.53; P 
= 0.027, and r = 0.60; P = 0.025, respectively). ADMA 
was also related to NOx plasma levels 3 mo after TIPS 
placement (r = 0.67; P = 0.009). Neither significant 
relations were present between arginine/ADMA ratios 
and NOx plasma levels nor between NOx concentrations 
and portosystemic pressure gradient.
Relations between dimethylarginines and hepatic and
renal function
ADMA was positively related to Child-Pugh score before 
and 3 mo after TIPS placement (r = 0.44; P = 0.034 and 
r = 0.59; P = 0.028, respectively). SDMA was positively 
related to Child-Pugh score 3 mo after TIPS placement 
(r = 0.66; P = 0.011).
SDMA was related to creatinine clearance rate before 
and 3 mo after TIPS placement (r = -0.70; P < 0.001, 
r = -0.85; P < 0.001, respectively). ADMA was also 
related to creatinine clearance rate 3 mo after TIPS 
placement (r = -0.70; P = 0.007).
Neither ADMA nor SDMA was related to porto-
systemic pressure gradient.
DISCUSSION
The main finding in the present study was an increase of  
the arginine/ADMA ratio three months after placement 
of  TIPS in cir rhotic patients. In addition, TIPS 
placement caused a decrease in SDMA levels which 
may be partially explained by an advantageous effect on 
renal function as reflected by an increase in creatinine 
clearance rate due to TIPS placement. Interestingly, when 
patients with and patients without renal dysfunction 
before TIPS placement were studied separately, both 
the arginine/ADMA ratio and the creatinine clearance 
rate improved significantly in patients with renal 
dysfunction before TIPS placement, while these changes 
were not seen in patients with normal renal function. 
The advantageous effect of  TIPS placement on renal 
function is also reflected by the strong and significant 
correlation between SDMA plasma levels and creatinine 
clearance before and particularly after TIPS placement. 
The relation between dimethylarginines and creatinine 
clearance rate has already been shown in patients with 
renal insufficiency[22]. Interestingly, the clearing of  SDMA 
is not only confined to the kidney, but the human liver 
also takes up substantial amounts of  SDMA[3]. Indeed, 
we also found a relation between SDMA and Child-
Pugh score, thereby underlining the reported SDMA 
clearing capacity of  the liver. Thus, increased SDMA 
levels in our studied cirrhotic patients may be caused by 
a combination of  renal and hepatic dysfunction. Also for 
ADMA, we observed increased plasma concentrations 
at baseline being also closely related to the severity of  
liver dysfunction. This is in accordance with the findings 
of  Lluch and coworkers[7] who likewise reported a direct 
relationship with the Child-Pugh score of  patients being 
evaluated.
The main metabolic route for ADMA is degradation 
via DDAH[23] and the liver, which has a high DDAH 
activity, has been shown to be an important regulator of  
plasma ADMA levels in both animals and humans[2,3]. 
In portal hypertensive conditions, a recent study of  
Mookerjee and coworkers[24] showed reduced DDAH 
expression and increased ADMA levels in liver tissue 
of  patients with severe alcoholic hepatitis. In addition, 
they suggested that elevated dimethylarginines may 
serve as a marker of  a deleterious outcome in patients 
with alcoholic hepatitis. Also, in patients undergoing 
liver transplantation, ADMA has been shown to be a 
potential marker of  acute allograft rejection[4]. Moreover, 
in cirrhotic animals, significantly decreased hepatic 
clearance of  ADMA has been demonstrated[25].
I n ou r s tudy popu l a t i on , s y s t em ic ADMA 
concentrations did not decrease after TIPS placement. 
This is not surprising considering the well-known 
TIPS-induced decrease in hepatic extraction capacity. 
In other words, we assumed ADMA levels to increase 
after TIPS placement due to shunting and thus less 
degradation by hepatic DDAH. However, this increasing 
effect on ADMA serum levels induced by the TIPS 
implantation may be offset by the observed increase in 
renal function and the most likely improvement in renal 
ADMA clearance. In fact, ADMA plasma levels strongly 
correlated with creatinine clearance 3 mo after TIPS 
placement. Moreover, these data are in accordance with 
the observation of  unaltered liver function represented by 
the lack of  significant changes in biochemical laboratory 
parameters indicating hepatic function nor in Child-Pugh 
score after TIPS placement. Because we did not measure 
arterial dimethylarginine concentrations nor organ blood 
flow of  the liver and kidney, no definite conclusions 
can be drawn about hepatic and renal elimination of  
dimethylarginines. Nonetheless, renal dysfunction often 
develops in patients with severe liver disease and a causal 
role for ADMA has been proposed in the development 
of  the hepatorenal syndrome[26]. Recently, Lluch and 
co-workers[16] studied dimethylarginine concentrations 
in cirrhotic patients with hepatorenal syndrome and 
confirmed this hypothesis. Moreover, they suggested that 
SDMA may be a marker of  renal dysfunction in cirrhotic 
patients. Therefore, the lack of  an increase in ADMA 
and actual decrease in SDMA levels may well contribute 
to the well-known beneficial effects of  TIPS with respect 
to neurohormonal status and kidney function in liver 
cirrhosis.
In l iver cir rhosis, Laleman and co-workers[25] 
substantiated the potential role of  ADMA in the 
Table 5  Plasma concentrations of NOx (µmol/L)
NOx Just before TIPS Directly after TIPS 3 mo after TIPS
Median IQR Median IQR Median IQR
Systemic vein 112 37-243 107 33-212 44   26-103
Portal vein   83 35-241   85 45-223 57 21-96
Hepatic vein   85 35-304   86 32-220 39 21-76
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pathogenesis of  impaired intrahepatic NO production. 
The known decrease in intrahepatic NO synthase activity 
in rats with biliary cirrhosis was found to be associated 
with an increase in circulating ADMA concentrations. 
In addition, endothelium-dependent vasorelaxation, 
measured in a liver perfusion model, was reduced in bile-
duct ligated rats and addition of  ADMA to the perfusate 
further blunted this vasodilatory response. However, 
in our study no association between ADMA levels and 
the severity of  portal hypertension could be detected. 
A potential explanation may be the mode of  action by 
which TIPS lowers portal pressure being independent 
f rom ADMA. Moreover, a l so SDMA has been 
reported to interfere with NO synthesis by competing 
with arginine for transport across cell membranes[10]. 
Especially high levels of  SDMA in combination with 
low arginine concentrations may decrease NO synthesis 
significantly and hemodynamical consequences may be 
the same as reported for ADMA[23,27].
The gut produces citrulline which is used by the 
kidneys to synthesize arginine. It can be hypothesized that 
a decrease in portal pressure will have an advantageous 
effect on blood flow and function of  the intestines, 
thereby increasing citrulline production by the gut and 
possibly enhancing renal arginine synthesis. Arginine 
is degraded in the liver that contains large amounts 
of  arginase which breaks down arginine into urea and 
ornithine. TIPS placement may lead to a decreased 
capacity to eliminate arginine in the liver because blood 
does not enter the hepatocyte, but shunts directly 
from a portal branch into the hepatic vein. This may 
explain the increase in arginine plasma levels after TIPS 
placement. As a precursor of  NO, this increase in 
arginine concentrations may enhance renal blood flow, 
thereby stimulating glomerular filtration rate and clearing 
a larger amount of  dimethylarginines from the systemic 
circulation. This compensatory increase in renal excretion 
of  dimethylarginines in fact will prevent a rise in ADMA 
levels induced by TIPS-induced portal decompression.
Liver cirrhosis is characterized by excessive systemic 
and particularly splanchnic NO production representing 
the pathophysiological hallmark in the development of  
the hyperdynamic circulatory syndrome. This vascular 
NO overproduction is stimulated by an in increase in 
portal pressure[28] and is an attempt to open the portal 
circulation and to enhance collateral blood flow in the 
systemic circulation bypassing the hepatic circulation. 
Besides a rise in arginine levels, the arginine/ADMA 
ratio increased significantly after TIPS placement. 
Theoretically, an increase in the arginine/ADMA ratio 
leads to an elevation in NO bioavailability. In our study, 
nonetheless, NOx plasma levels showed a decreasing 
tendency after TIPS placement. While no relationship 
was found between NOx and the arginine/ADMA 
ratio, both ADMA and SDMA were positively related 
to NOx levels. This finding substantiates the hypothesis 
that dimethylarginines might oppose the peripheral 
vasodilation caused by excessive systemic NO production 
during liver cirrhosis[7]. It can be hypothesized that after 
TIPS placement, portal pressure drops and thus the 
main stimulus for splanchnic NO overproduction is 
greatly attenuated. In addition, renal and probably also 
gut function improve, thereby causing arginine synthesis 
(via gut-derived citrulline) by the kidney to increase. 
Furthermore, ADMA slightly decreases due to enhanced 
function of  the kidney causing the arginine/ADMA ratio 
to increase. This is advantageous for the y+ pump that is 
now able to transport more arginine into the cell, where 
it is converted to NO. The increased arginine/ADMA 
ratio after TIPS may result in a better NO-availability on 
tissue level, while systemic (plasma) NO is decreased due 
to less splanchnic NO release.
In conclusion, the main finding of  the present study 
was a significant increase in the arginine/ADMA ratio in 
cirrhotic patients 3 mo after TIPS placement. In addition, 
TIPS enhanced renal function and concomitantly 
significantly lowered systemic SDMA levels, but did not 
change hepatic function. In line with this unaltered liver 
function, no significant decline in ADMA plasma levels 
could be detected, thereby confirming the major role of  
the liver as ADMA clearing organ.
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 COMMENTS
Background
Asymmetric dimethylarginine (ADMA) plays a regulatory role in the arginine-
nitric oxide (NO) pathway by inhibiting the enzyme NO synthase. In addition, 
dimethylarginines may play an important pathophysiological role in liver 
cirrhosis because this disease is characterised by endothelial dysfunction 
and NO deficiency in the intrahepatic circulation. In cirrhotic patients, 
elevated peripheral ADMA and NO levels have been reported and it has been 
suggested that ADMA might oppose the peripheral vasodilation caused by 
excessive systemic NO production during liver cirrhosis. In order to analyse 
dimethylarginine plasma levels in cirrhotic humans, authors studied patients 
receiving transjugular intrahepatic portosystemic shunt (TIPS).
Research frontiers
Elevated ADMA levels have been reported in patients eligible for liver 
transplantation in postoperative patients undergoing major liver resection, in 
patients suffering from decompensated alcoholic cirrhosis, and in critically 
ill patients with hepatic dysfunction. In fact, increased intrahepatic vascular 
resistance in cirrhosis is not only due to structural changes, but also due to a 
dynamic component. It has been suggested that an alteration in intrahepatic 
ADMA levels may lead to endothelial dysfunction and increased intrahepatic 
resistance. In cirrhotic patients, elevated peripheral ADMA and NO levels have 
been reported and it has been suggested that ADMA might oppose the peripheral 
vasodilation caused by excessive systemic NO production during liver cirrhosis.
Innovations and breakthroughs
This study shows an increase of the arginine/ADMA ratio after TIPS placement 
suggesting an increase in intracellular NO bioavailability. In addition, 
this study suggests that TIPS placement does not alter dimethylarginine 
dimethylaminohydrolase (DDAH) activity and confirms the major role of the liver 
as ADMA clearing organ.
Applications
TIPS placement is associated with an increased arginine/ADMA ratio 
suggesting an increased NO bioavailability which could have a positive effect 
on the microcirculation of important organs.
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Peer review
In this study, the levels of ADMA, symmetric dimethylarginine (SDMA) and 
arginine in caval/portal and hepatic vein as well as the NOx plasma levels in 
patients with cirrhosis were analyzed. Most of patients enrolled in this study 
suffered from alcohol-induced liver disease. The key finding of the manuscript is 
that arginine levels increase after TIPS-placement. The study is interesting and 
well performed.
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